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A bs tr ac t
Background
In sub-Saharan Africa, bacterial meningitis is common and is associated with a high 
mortality. Adjuvant therapy with corticosteroids reduces mortality among adults in 
the developed world, but it has not been adequately tested in developing countries 
or in the context of advanced human immunodeficiency virus (HIV) infection.
Methods 
We conducted a randomized, double-blind, placebo-controlled trial of dexametha-
sone (16 mg twice daily for 4 days) and an open-label trial of intramuscular versus in-
travenous ceftriaxone (2 g twice daily for 10 days) in adults with an admission diag-
nosis of bacterial meningitis in Blantyre, Malawi. The primary outcome was death at 
40 days after randomization.
Results 
A total of 465 patients, 90% of whom were HIV-positive, were randomly assigned to 
receive dexamethasone (233 patients) or placebo (232 patients) plus intramuscular cef-
triaxone (230 patients) or intravenous ceftriaxone (235 patients). There was no sig-
nificant difference in mortality at 40 days in the corticosteroid group (129 of 231 
patients) as compared with the placebo group (120 of 228 patients) by intention-to-
treat analysis (odds ratio, 1.14; 95% confidence interval [CI], 0.79 to 1.64) or when 
the analysis was restricted to patients with proven pneumococcal meningitis (68 of 
129 patients receiving corticosteroids vs. 72 of 143 patients receiving placebo) (odds 
ratio, 1.10; 95% CI, 0.68 to 1.77). There were no significant differences between groups 
in the outcomes of disability and death combined, hearing impairment, and adverse 
events. There was no difference in mortality with intravenous ceftriaxone (121 of 230 
patients) as compared with intramuscular ceftriaxone (128 of 229 patients) (odds ratio, 
0.88; 95% CI, 0.61 to 1.27).
Conclusions 
Adjuvant therapy with dexamethasone for bacterial meningitis in adults from an 
area with a high prevalence of HIV did not reduce mortality or morbidity. In this 
setting, intramuscular administration was not inferior to intravenous administra-
tion of ceftriaxone for bacterial meningitis. (Current Controlled Trials number, 
ISRCTN31371499.)
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Bacterial meningitis ranks 10th as a cause of death from infectious diseases worldwide1 and is common in the develop-
ing world.2 Its incidence in Malawi, where most 
adult medical inpatients have advanced human im-
munodeficiency virus (HIV) infection, is 50 per 
100,000 adult person-years,3 more than 10 times 
the incidence seen in industrialized countries.4 
Streptococcus pneumoniae is the most common caus-
ative organism, with a mortality of 65%5 as com-
pared with 26 to 34%6,7 in industrialized countries 
before the introduction of adjuvant therapy with 
corticosteroids.
The host inflammatory response in bacterial 
meningitis contributes to neuronal injury 8 and can 
be modulated by corticosteroids.9 In Europe, corti-
costeroids given as adjuvant therapy reduce mor-
tality among adults, particularly in pneumococcal 
meningitis,7 and reduce hearing loss in children 
after Haemophilus inf luenzae type b meningitis.10 
Consequently, corticosteroids have been incorpo-
rated into therapeutic guidelines11,12 and are rec-
ommended particularly for pneumococcal menin-
gitis.13 Data from developing countries or from 
areas of high prevalence of HIV regarding the 
use of corticosteroids in bacterial meningitis are 
scarce. In Egypt, an open-label trial that included 
adults and children suggested a reduction in mor-
tality for patients with pneumococcal meningi-
tis.14 A pediatric trial in Malawi showed no ben-
efit from corticosteroids in children with bacterial 
meningitis.15 Trials restricted to adults in devel-
oping countries have either shown no benefit or 
lacked sufficient power.16-19 Corticosteroids are 
inexpensive, safe, and accessible, and they would 
therefore be appropriate for such patients if they 
prove to be effective. We conducted a double-blind, 
randomized, placebo-controlled trial of adjuvant 
therapy with dexamethasone in adults with bacte-
rial meningitis in Malawi.
In many parts of sub-Saharan Africa, intrave-
nous therapy cannot be easily administered. In-
tramuscular ceftriaxone therapy has been assessed 
in bacterial meningitis in children but not in 
adults.20,21 If intramuscular therapy is shown to 
be effective, it may facilitate early antibiotic thera-
py in remote areas. Thus, patients also were ran-
domly assigned in a factorial design to receive 
antibiotic therapy either intramuscularly or intra-
venously.
Me thods
The study was conducted between May 2002 and 
January 2005 in Queen Elizabeth Central Hospi-
tal in Blantyre, Malawi. This hospital offers free 
care to 10,000 adult medical inpatients per year, 
70% of whom have HIV infection. All patients who 
had a lumbar puncture were referred immediately 
to a member of the trial staff for assessment of 
eligibility. Inclusion criteria were a clinical suspi-
cion of bacterial meningitis and either positive 
cerebrospinal fluid on microscopy (defined as or-
ganisms seen on Gram’s stain or more than 100 
white cells per cubic millimeter, of which more 
than 50% were neutrophils) or cloudy cerebrospi-
nal fluid when immediate microscopy was unavail-
able. Exclusion criteria were age younger than 16 
years, corticosteroids received in the previous 48 
hours, cryptococcus detected in cerebrospinal fluid 
specimens by means of microscopy, or contrain-
dications to study drugs. Patients or their legal 
guardians provided written informed consent or, 
if they were unable to read or write, independently 
witnessed verbal consent before recruitment. The 
study design and data collection were conducted 
by members of the University of Malawi College 
of Medicine. The funding body (Meningitis Re-
search Foundation) and the pharmaceutical com-
panies donating drugs (Emcure Pharmaceuticals 
and Cipla) played no part in the design, conduct, 
analysis, or reporting of the results, nor were they 
involved in the writing or approval of the manu-
script. The study was approved by the research eth-
ics committees of the University of Malawi College 
of Medicine and the Liverpool School of Tropical 
Medicine.
Patients were randomly assigned to receive ei-
ther dexamethasone (Dexacip, Cipla) at a dose of 
16 mg in 4 ml of sterile water twice daily or place-
bo (buffered sterile water, Cipla) at a dose of 4 ml 
twice daily intravenously for 4 days, and either in-
tramuscular or intravenous ceftriaxone (C-Tri, Em-
cure Pharmaceuticals) at a dose of 2 g twice daily 
for 10 days. Dexamethasone or placebo was ad-
ministered immediately before the administration 
of ceftriaxone. Patients received care in the gener-
al medical wards. When necessary, patients were 
transferred to a high-dependency unit and antibi-
otic therapy was modified according to antimicro-
bial-sensitivity patterns and clinical progress.
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Randomization was performed by computer-
generated blocks of eight in a two-way factorial 
design. Notification of treatment allocation was 
provided in sealed, opaque envelopes assigned to 
consecutively recruited patients; opening the en-
velope constituted entry to the trial. Dexametha-
sone and placebo were presented as clear, color-
less fluid in identical packaging labeled only with 
the randomization number; the corticosteroid 
component of the trial was therefore conducted 
in a double-blind fashion.
Cerebrospinal fluid specimens were examined 
by means of microscopy for cell and differential 
counts, and by staining with India ink. A Gram’s 
stain procedure was performed if the sample was 
turbid or had more than 10 white cells per cubic 
millimeter. Centrifuged cerebrospinal fluid depos-
its were incubated on sheep-blood agar in a can-
dle-extinction jar at 37°C for 48 hours and isolates 
were identified by means of standard techniques.22 
Blood was cultured at 37°C for a minimum of 48 
hours (BacT/Alert, bioMérieux). In the first 51 con-
secutive cerebrospinal fluid specimens for which 
Gram’s stain and culture were negative, poly-
merase chain reaction (PCR) for meningococ-
cus and pneumococcus was performed.23 Antibi-
otic sensitivity was assessed by means of disk 
diffusion.24
For patients who survived to discharge, HIV 
testing with pretest and post-test counseling was 
performed after consent was obtained. In patients 
who died, HIV testing was performed at least 
3 months after death. Testing was performed by 
means of two enzyme-linked immunosorbent as-
say tests (Vironostika, Organon Teknika, and 
HIV-1/HIV-2 Go EIA, Abbott); discordant results 
were tested by means of a third test (Uni-Gold, 
Trinity Biotech).
Patients were treated in the hospital for a mini-
mum of 10 days and were evaluated at 40 days and 
at 6 months. Clinically evident adverse events were 
recorded systematically throughout the trial pe-
riod. At follow-up, patients had a standardized 
neurologic examination and a hearing assessment. 
Patients who did not return for follow-up appoint-
ments were visited at home. Details regarding 
hearing and disability assessment are presented 
in the Supplementary Appendix, available with the 
full text of this article at www.nejm.org.
The predefined primary outcome was mortal-
ity at 40 days from randomization by intention-
to-treat analysis. Secondary outcomes were time to 
death, combined disability and death as defined 
by the Glasgow Outcome Score25 at day 40, hear-
ing impairment at day 40, death at 10 days, and 
death at 6 months.
Subgroup analyses were performed for patients 
with proven or probable bacterial meningitis, 
proven bacterial meningitis alone, and proven 
pneumococcal meningitis. Proven bacterial men-
ingitis was defined as identification of an organ-
ism from a cerebrospinal fluid specimen by means 
of microscopy, culture, or PCR or from blood cul-
ture in the context of a cerebrospinal fluid speci-
men containing a white-cell count of more than 
100 per cubic millimeter with more than 50% 
neutrophils. Probable bacterial meningitis was 
defined as a cerebrospinal fluid specimen contain-
ing a cell count of more than 100 per cubic mil-
limeter with more than 50% neutrophils without 
identification of an organism. The analytic plan 
was approved by the data and safety monitoring 
board and the trial steering committee before un-
blinding. A planned interim analysis was per-
formed by the data and safety monitoring board 
after 100 deaths.
On the basis of a background mortality of 56% 
and an ability to detect a 20% or greater differ-
ence in mortality, the initial sample size of 660 
patients was modified to 420 patients to detect 
a 30% difference after publication of the results 
of a European trial that showed a relative risk of 
death of 0.59 for corticosteroid treatment.7 For 
the primary outcome, a P value less than 0.05 was 
considered to indicate statistical significance. All 
P values are two-sided. Odds ratios and 95% con-
fidence intervals were calculated and adjusted for 
predefined prognostic factors in a logistic-regres-
sion model. The difference in time to death 
through 40 days between the groups was tested 
with the use of Cox proportional-hazard ratios. 
Data were analyzed with the use of Stata software, 
version 8.2.
R esult s
Of 522 consecutive patients who met the entry 
criteria, 465 (89.0%) underwent randomization. 
Of those who underwent randomization, 233 pa-
tients (50.1%) received corticosteroids and 232 
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(49.9%) received placebo (Fig. 1). HIV serologic sta-
tus was available for 434 patients (93.3%), of whom 
389 (89.6%) were HIV-positive. Four patients were 
known to be HIV-positive at the time of admission; 
none were receiving antiretroviral therapy or pro-
phylaxis against opportunistic infections. The me-
dian CD4 cell count on admission in 101 consecu-
tively recruited HIV-positive patients was 102 per 
cubic millimeter (interquartile range, 51 to 169). 
Further details on CD4 cell count testing and HIV 
aftercare are included in the Supplementary Ap-
pendix.
Clinical characteristics and results of labora-
tory tests were similar in the comparison groups 
(Table 1). A total of 325 patients (70%), 158 of 
whom were in the corticosteroid group, had mi-
33p9
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215 Had a nondiagnostic cerebro-
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Figure 1. Enrollment, Randomization, and Analysis of Patients.
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crobiologically proven bacterial meningitis. A total 
of 102 patients (22%), 52 of whom were in the 
corticosteroid group, had probable bacterial men-
ingitis. A total of 38 patients (8%), 23 of whom 
were in the corticosteroid group, underwent ran-
domization but were subsequently found to have 
diagnoses other than bacterial meningitis; 20 had 
cryptococcal meningitis (12 of whom were in the 
corticosteroid group), 7 had tuberculous menin-
gitis (6 of whom were in the corticosteroid group), 
and 11 had traumatic lumbar puncture (5 of whom 
were in the corticosteroid group). Four patients 
underwent randomization in error; two were 
younger than 16 years of age, one had a cerebro-
spinal fluid specimen with a white-cell count of 
92 per cubic millimeter, and one had received oral 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Corticosteroid 
(N = 233)
Placebo  
(N = 232)
Intramuscular  
Ceftriaxone 
(N = 230)
Intravenous  
Ceftriaxone 
(N = 235)
Age — yr 32.3±10.1 32.6±11.4 32.4±10.9 32.6±10.6
Male sex — no. (%) 122 (52) 108 (47) 115 (50) 115 (49)
Glasgow Coma Scale score† 10.7±3.5 10.8±3.3 11±3.4 10.4±3.4
Hemoglobin — g/dl 10.4±2.8 10.7±3.1 10.5±3.0 10.7±2.8
Median time to presentation — hr (interquartile range) 72 (48–120) 72 (48–144) 72 (48–144) 72 (48–120)
Previous treatment with antimicrobial agents — no. (%)‡
Oral 35 (15) 42 (18) 34 (15) 43 (18)
Parenteral 48 (21) 47 (20) 49 (21) 46 (20)
Not known 4 (2) 8 (3) 6 (3) 6 (3)
Microbiologic diagnosis — no. (%)     
Proven bacterial 158 (68) 167 (72) 155 (67) 170 (72)
Streptococcus pneumoniae 130 (56) 145 (62) 131 (57) 144 (61)
Neisseria meningitidis 10 (4) 10 (4) 13 (6) 7 (3)
Other gram­negative organisms§ 15 (6) 10 (4) 9 (4) 16 (7)
Other¶ 3 (1) 2 (1) 2 (1) 3 (1)
Probable bacterial (no organism identified) 52 (22) 50 (22) 56 (24) 46 (20)
Not bacterial meningitis 23 (10) 15 (6) 19 (8) 19 (8)
Cryptococcal meningitis‖ 12 (5) 8 (3) 8 (3) 12 (5)
Mycobacterium tuberculosis 6 (3) 1 (0.4) 5 (2) 2 (1)
Not meningitis 5 (2) 6 (3) 6 (3) 5 (2)
Positive blood culture — no. (%)** 82 (35) 68 (29) 69 (30) 81 (34)
Blood culture unavailable — no. (%) 6 (3) 5 (2) 3 (1) 8 (3)
HIV­positive — no./total no. tested (%) 194/216 (90) 195/218 (89) 191/215 (89) 198/219 (90)
HIV status not known — no. (%) 17 (7) 14 (6) 15 (7) 16 (7)
Randomly assigned to receive intramuscular ceftriaxone — 
no. (%)
117 (50) 113 (49)   
Randomly assigned to receive corticosteroids — no. (%) 117 (51) 116 (49)
* Plus–minus values are means ±SD.
† The Glasgow Coma Scale ranges from 3 to 15, with 3 indicating that the patient is unresponsive and 15 indicating that the patient is fully alert.
‡ Details regarding pretreatment antibiotics are available in Table S1 in the Supplementary Appendix. 
§ Other gram­negative organisms were Escherichia coli (in 11 patients), non­typhi salmonella (in 7), Haemophilus influenzae  
(in 3), klebsiella species (in 3), and Enterobacter gergoviae (in 1).
¶ Other bacteria were Staphylococcus aureus (in 2 patients) and α­hemolytic streptococci (in 3).
‖ Of 20 patients, 10 were categorized as having probable bacterial meningitis on the basis of the cell and differential counts from the cerebrospi­
nal fluid specimen but were found to have cryptococcal meningitis either after prolonged incubation or after repeated lumbar puncture.
** Of 150 positive blood cultures, 7 were positive for Cryptococcus neoformans.
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prednisolone within 48 hours before recruitment. 
All patients were included in the intention-to-treat 
analysis.
Organisms were seen on Gram’s stain in 263 of 
452 specimens (58%). A total of 39 patients had a 
positive cerebrospinal fluid culture without a posi-
tive Gram’s stain, and 6 patients had a positive 
blood culture with a cerebrospinal fluid specimen 
showing neutrophil pleocytosis but a negative 
Gram’s stain and culture. Of 51 consecutive cul-
ture-negative cerebrospinal fluid specimens tested 
by means of PCR, 17 were positive for either pneu-
mococcus (in 12 patients) or meningococcus (in 5) 
and were classified as proven bacterial meningitis. 
Reclassification of these cases as probable bacte-
rial meningitis did not affect the interpretation of 
the effect of corticosteroids in any subgroup. Ten 
patients had microbiologically proven dual infec-
tion; all had pneumococcal meningitis with con-
current non-typhi salmonella septicemia (in seven 
patients), Enterococcus faecalis septicemia (in one pa-
tient), or cryptococcemia (in two patients).
All patients who underwent randomization re-
ceived at least one dose of the assigned treatment. 
All 437 patients who met the criteria for proven or 
probable bacterial meningitis on the basis of find-
ings from cerebrospinal fluid specimens received 
corticosteroids or placebo for 4 days or until death 
and ceftriaxone for 10 days or until death. Of the 
remaining 28 patients who underwent random-
ization, 5 received corticosteroids or placebo for 
4 days or until death and 3 received ceftriaxone for 
10 days or until death. Corticosteroids were added 
to therapy after the completion of the initial 4 days 
of therapy for three patients; two patients had ce-
rebral edema (one of whom was in the cortico-
steroid group), and one patient in the corticoste-
roid group had a presumed drug rash. The results 
for these patients were analyzed according to the 
initial randomization.
The outcome at 40 days from recruitment was 
available for 459 patients (98.7%). Of six patients 
lost to follow-up (including two in the corticoste-
roid group), two did not have bacterial meningitis 
and one was withdrawn from the trial therapy 
because of age (14 years). Overall mortality was 
249 of 459 (54.2%). The association between base-
line factors and mortality is shown in Table 2.
Mortality at 40 days from enrollment was 129 
of 231 patients in the corticosteroid group (55.8%) 
and 120 of 228 patients in the placebo group 
(52.6%) (odds ratio, 1.14; 95% confidence interval 
[CI], 0.79 to 1.64; P = 0.49). The adjusted odds ratio 
was 1.13 (95% CI, 0.73 to 1.76). An on-treatment 
analysis, censoring events after premature discon-
tinuation of the study drug, shows a similar mor-
tality of 125 of 222 patients in the corticosteroid 
group (56.3%) and 117 of 223 patients in the pla-
cebo group (52.5%). Given the 80% power of this 
study, a one-sided test excludes a reduction in 
40-day mortality in the corticosteroid group of 
23% or greater. Time to death was similar in both 
groups (hazard ratio, 1.07; 95% CI, 0.84 to 1.38) 
(Fig. 2). When an interaction term for the com-
parison of intravenous versus intramuscular cef-
triaxone is included, the odds ratio for mortality 
Table 2. Association between Baseline Characteristics and Mortality at 40 Days.
Characteristic Univariate Analysis Multivariate Analysis*
Odds Ratio (95% CI) P Value Odds Ratio (95% CI ) P Value
Male sex 1.09 (0.75–1.57) 0.67 0.98 (0.62–1.55) 0.94
Age ≥32 yr† 1.92 (1.32–2.79) 0.001 1.96 (1.24–3.10) 0.004
Glasgow Coma Scale score <12‡ 2.77 (1.90–4.06) <0.001 4.10 (2.51–6.69) <0.001
Hemoglobin <10 g/dl§ 1.82 (1.23–2.69) 0.003 2.19 (1.39–3.45) 0.001
>48­hr history¶ 1.64 (1.07–2.50) 0.02 1.48 (0.87–2.49) 0.14
Pneumococcal infection 0.76 (0.52–1.10) 0.15 0.56 (0.34–0.93) 0.02
Previous treatment with antibiotics 1.19 (0.81–1.75) 0.364 0.93 (0.58–1.49) 0.76
HIV­positive 1.96 (1.05–3.69) 0.035 1.35 (0.67–2.72) 0.40
* All factors in this table were included in the final model.
† The mean age was 32.5 years.
‡ The Glasgow Coma Scale ranges from 3 to 15, with 3 indicating that the patient is unresponsive and 15 indicating that 
the patient is fully alert. The median Glasgow Coma Scale score on admission was 11.
§  The median hemoglobin level on admission was 10.4 g per deciliter.
¶ A history of >48 hours was considered to indicate late presentation.
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at day 40 in the corticosteroid group becomes 1.09 
(95% CI, 0.64 to 1.83).
The results of the intention-to-treat analysis and 
the predefined analyses for patients with proven 
and probable bacterial meningitis, proven bacte-
rial meningitis, and pneumococcal meningitis in 
the corticosteroid trial are shown in Table 3. There 
were no differences in the rates of death, disability 
and death, or clinically detectable hearing loss at 
40 days or in mortality at 10 days or at 6 months. 
Further exploratory analyses showed no evidence 
that corticosteroids were effective in any subgroup 
(Table S2 in the Supplementary Appendix). Pat-
terns of hearing loss and of disability among sur-
vivors are shown in Tables S3A and S3B in the 
Supplementary Appendix. As compared with pa-
tients who received placebo, the temperatures of 
patients in the corticosteroid group were lower 
during treatment (mean difference, 0.49°C at 
day 4; P<0.001) (Fig. S1 in the Supplementary 
Appendix).
In the trial concerning the route of antibiotic 
administration, mortality at 40 days was 121 of 
230 patients in the intravenous group (52.6%) and 
128 of 229 patients in the intramuscular group 
(55.9%) (odds ratio, 0.88; 95% CI, 0.61 to 1.26) 
(Table 4). An on-treatment analysis, censoring 
events after premature discontinuation of ceftri-
axone, shows a similar mortality of 119 of 225 
patients in the intravenous group (52.9%) and 
124 of 219 patients in the intramuscular group 
(56.6%). Given the actual 80% power of this study, 
a two-sided test excludes an increase or decrease 
in 40-day mortality in the intramuscular group 
of 25% and 24%, respectively. When an interaction 
term for the comparison of corticosteroid and pla-
cebo administration is included, the odds ratio 
for mortality at 40 days in the intravenous group 
becomes 0.84 (95% CI, 0.5 to 1.14). In seven pa-
tients, pain during intramuscular injection was 
sufficiently distressing for clinicians to switch to 
intravenous treatment. Only one isolate (S. pneu-
moniae) showed reduced susceptibility to ceftriax-
one (Table S4 in the Supplementary Appendix).
There were no differences in the rates of ad-
verse events potentially related to corticosteroid 
therapy and none resulted in withdrawal of pa-
tients from the trial (Table S5 in the Supplemen-
tary Appendix). Nineteen patients had adverse 
events that were more likely to be due to antibi-
otics than corticosteroids; nine patients had late 
fever (including seven patients in the corticoste-
roid group), five had rash (including two in the 
corticosteroid group), three had diarrhea (includ-
ing one in the corticosteroid group), and two had 
jaundice (both of whom were in the corticosteroid 
group).
Discussion
The greatest burden of bacterial meningitis in 
adults occurs in developing countries where mor-
tality rates are high. If effective, corticosteroids as 
adjuvant therapy would represent an affordable 
and appropriate intervention. The results of our 
study show that, in a setting where the majority 
of patients are likely to have advanced HIV infec-
tion, where presentation tends to be late, and where 
S. pneumoniae is the predominant pathogen, adju-
vant therapy with dexamethasone for bacterial 
meningitis in adults confers no advantage with re-
gard to mortality or morbidity at 40 days.
In our study, mortality was substantially higher 
than in it is in industrialized settings, but it was 
typical for a low-resource setting in sub-Saharan 
Africa. It was lower than in previous studies in 
Malawi,3,5 probably due to the use of ceftriaxone 
(rather than penicillin plus chloramphenicol) and 
the effect of improved care as a result of the pa-
tients’ inclusion in a clinical trial.
The negative findings from this study, pre-
dominantly in patients with advanced HIV disease, 
contrast with those of a European trial of corti-
costeroids involving 301 adults with meningitis.7 
The European trial showed an overall reduction of 
mortality from 15% to 7% at 8 weeks (P=0.04), 
and the benefit of corticosteroids was most marked 
in patients with pneumococcal meningitis. The 
current findings are similar to those of a large 
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Figure 2. Kaplan–Meier Estimates of Survival for 459 Patients through  
Day 40.
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trial involving children with meningitis in Mala-
wi,15 which showed no survival advantage with 
corticosteroids.
Several differences in the study populations, 
alone or in combination, may explain the dispar-
ity between the results from Malawi and else-
where. In the current trial, of 434 patients for 
whom serologic status was known, 90% were HIV-
positive and the majority were likely to have had 
advanced disease. Although HIV status was not 
reported in the European study, it is likely that 
the proportion of HIV-positive patients was 
much lower. HIV is a risk factor for the develop-
ment of invasive pneumococcal disease26 and, al-
though our study suggests that HIV is a predic-
tor of mortality, it has previously been suggested 
that the outcome from meningitis in HIV-infected 
patients is better than that in HIV-negative pa-
tients.27 Since patients with HIV already have an 
attenuated host response, corticosteroids may not 
Table 3. Outcome for Patients Who Received Corticosteroid versus Placebo.
Outcome Corticosteroid Placebo Odds Ratio (95% CI)*
Unadjusted Adjusted
no./total no. (%)
Intention-to-treat population
Death, day 40 129/231 (56) 120/228 (53) 1.14 (0.79–1.64) 1.13 (0.73–1.76)
Disability or death, day 40† 150/227 (66) 146/224 (65) 1.04 (0.71–1.54) 1.01 (0.64–1.60)
Hearing loss, day 40 30/96 (31) 36/99 (36) 0.80 (0.44–1.44) 0.76 (0.37–1.54)
Death, day 10 99/232 (43) 96/230 (42) 1.04 (0.72–1.50) 1.01 (0.65–1.57)
Death, 6 mo 140/204 (69) 127/205 (62) 1.34 (0.89–2.02) 1.26 (0.77–2.06)
Proven or probable bacterial  
meningitis‡
Death, day 40 120/216 (56) 114/217 (53) 1.13 (0.77–1.65) 1.11 (0.71–1.73)
Disability or death, day 40 140/213 (66) 139/216 (64) 1.06 (0.71–1.58) 1.01 (0.63–1.60)
Hearing loss, day 40 30/90 (33) 35/97 (36) 0.86 (0.47–1.56) 0.82 (0.40–1.68)
Death, day 10 94/217 (43) 93/217 (43) 1.04 (0.71–1.51) 1.04 (0.66–1.63)
Death, 6 mo 130/194 (67) 120/194 (62) 1.25 (0.83–1.90) 1.25 (0.75–2.02)
Proven bacterial meningitis
Death, day 40 82/157 (52) 80/165 (48) 1.16 (0.75–1.80) 1.13 (0.67–1.90)
Disability or death, day 40 99/155 (64) 99/164 (60) 1.16 (0.74–1.83) 1.04 (0.60–1.79)
Hearing loss, day 40 26/72 (36) 30/79 (38) 0.92 (0.48–1.79) 0.87 (0.39–1.93)
Death, day 10 70/158 (44) 71/166 (43) 1.06 (0.69–1.65) 1.08 (0.64–1.84)
Death, 6 mo 91/143 (64) 84/148 (57) 1.33 (0.83–2.14) 1.37 (0.77–2.41)
Proven pneumococcal meningitis
Death, day 40 68/129 (53) 72/143 (50) 1.10 (0.68–1.77) 1.09 (0.62–1.93)
Disability or death, day 40 81/128 (63) 89/142 (63) 1.03 (0.63–1.68) 0.96 (0.53–1.73)
Hearing loss, day 40 22/59 (37) 28/65 (43) 0.79 (0.38–1.62) 0.81 (0.35–1.88)
Death, day 10 61/130 (47) 65/144 (45) 1.07 (0.67–1.73) 1.04 (0.58–1.85)
Death, 6 mo 74/118 (63) 76/127 (60) 1.13 (0.67–1.89) 1.25 (0.67–2.32)
* The adjusted odds ratios are adjusted for age, sex, HIV status, time from onset of symptoms to presentation at the 
hospital, previous exposure to antibiotics, Glasgow Coma Scale score, hemoglobin level, pneumococcal or nonpneu­
mococcal disease, and route of antibiotic administration. Age, length of history, Glasgow Coma Scale score, and hemo­
globin level are continuous variables.
† Eight patients (four in each group) were known to be alive, but the investigators were unable to verify whether they had 
a disability.
‡ This category includes 10 patients classified as having probable bacterial meningitis (>100 white cells per cubic milli­
meter, of which >50% were neutrophils) but who subsequently were found to have cryptococcal disease after prolonged 
culture or repeated lumbar puncture.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 14, 2014. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Corticosteroids for Bacterial Meningitis in Sub-Sahar an Africa
n engl j med 357;24 www.nejm.org december 13, 2007 2449
confer any additional advantage. Since only 45 
patients in the current trial were known to be HIV-
negative, we were unable to test this hypothesis, 
although it would be consistent with the point es-
timates for mortality among HIV-negative as com-
pared with HIV-positive patients.
There are many barriers to accessing health 
care in sub-Saharan Africa, and presentation is 
often delayed. The median length of history in the 
current study was 72 hours, as compared with 
24 hours in the European study. Delayed presen-
tation was associated with a poorer outcome in 
the current trial, although adjusting for this fac-
tor in the analysis had no effect. The general 
health of participants was likely to be substan-
tially lower in the current study (e.g., a mean he-
moglobin level of 10.4 g per deciliter at admission) 
as compared with the European study, and the 
intensity of medical assistance was inevitably low-
er. Such factors almost certainly contributed to the 
higher mortality reported here, but they cannot 
explain the lack of benefit from corticosteroids.
A total of 36% of the patients in the European 
study had pneumococcal meningitis, and these 
patients received the greatest benefit from corti-
costeroids as adjuvant therapy. In the current trial, 
59% of the patients had pneumococcal disease, 
but they did not benefit from corticosteroid thera-
py. It seems unlikely, therefore, that the organism 
mix explains the difference between the results 
of the two studies. We had insufficient numbers 
of patients to perform a reliable subgroup analy-
sis for other organisms, but comparable trials have 
not shown a benefit of corticosteroids in patients 
with meningococcal meningitis. Recent exposure 
to antibiotic therapy was not an exclusion crite-
rion, since this would have made the study non-
representative of African practice. The majority of 
patients did not receive antibiotics before recruit-
ment, and analysis restricted to these patients did 
not show any advantage of corticosteroid therapy.
Given the mean weight of men in Malawi 
(60.0 kg)28 as compared with that of men in Eu-
rope (80.6 kg),29 the dosing schedule used for 
dexamethasone (16 mg twice daily, vs. 10 mg every 
6 hours in the European study) reflects an equiv-
alent total daily dose for weight. Thus, consider-
ing the long biologic half-life of dexamethasone, 
the difference in dosing regimens between the 
studies is unlikely to account for differences in the 
results.
We consider that the results of this study based 
on 249 deaths, as compared with 32 deaths in the 
European study, are unlikely to be a chance find-
ing. The negative results of the current study sug-
gest that the evidence of the benefit of corticoste-
roids from a European trial cannot be extrapolated 
to the very different setting of a high prevalence 
of HIV infection in sub-Saharan Africa. The im-
plications for HIV-positive adults with pneumo-
coccal meningitis outside Africa or those receiv-
ing antiretroviral therapy are unclear. The results 
from this study suggest that the intramuscular 
administration of ceftriaxone is an effective ther-
apy for bacterial meningitis in areas where ac-
cess to intravenous therapy is limited.
This trial does not provide support for the rou-
tine inclusion of corticosteroids in the manage-
ment of adult bacterial meningitis in resource-poor 
areas where pneumococcus is the primary patho-
gen and where a substantial proportion of patients 
are likely to have advanced HIV disease. Until al-
ternative adjuvant therapies prove effective or ap-
propriate vaccines become widely available,30 mor-
Table 4. Mortality at 40 Days for Intravenous versus Intramuscular Ceftriaxone.
Group
Intravenous  
Ceftriaxone
Intramuscular 
Ceftriaxone Odds Ratio (95% CI)*
Unadjusted Adjusted
no./total no. (%)
Intention­to­treat population 121/230 (53) 128/229 (56) 0.88 (0.61–1.27) 0.84 (0.54–1.30)
Proven and probable bacterial meningitis 115/221 (52) 119/212 (56) 0.85 (0.58–1.24) 0.79 (0.51–1.23)
Proven bacterial meningitis 87/168 (52) 75/154 (49) 1.13 (0.73–1.75) 0.92 (0.55–1.56)
Pneumococcal meningitis 74/142 (52) 66/130 (51) 1.06 (0.66–1.70) 0.87 (0.49–1.54)
* These odds ratios were adjusted for age, sex, HIV status, time from the onset of symptoms to presentation at the hos­
pital, previous exposure to antibiotics, Glasgow Coma Scale score, hemoglobin level, receipt of corticosteroid or place­
bo, and pneumococcal or nonpneumococcal disease. Age, length of history, Glasgow Coma Scale score, and hemoglo­
bin level are continuous variables.
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tality from bacterial meningitis in such settings 
is likely to remain unacceptably high.
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